Product Description
Cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT06464965?term=CB+CAR-NK182&draw=2&rank=1)
Mechanisms of Action: NK Cells,CLDN18.2
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang Provincial Hospital of Traditional Chinese Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Adenocarcinoma|Gastrointestinal Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT06464965 | P1 |
Recruiting |
Pancreatic Cancer|Gastrointestinal Cancer|Adenocarcinoma |
2025-06-13 |